Zimbabwe has declined a significant American healthcare agreement valued at 367 million US dollars (272 million pounds) over five years due to Washington's request for confidential biological samples.
The decision was revealed after a official document dated December was leaked, which showed President Emmerson Mnangagwa deemed the arrangement was "lopsided".
An official spokesman has since stated that the US was requesting genetic material for scientific study and commercial purposes but was not willing to share the benefits from any future treatments.
"We are forced to start the difficult and regrettable task of winding down our health assistance in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont in a statement.
Her embassy indicated the United States had provided more than $1.9bn as health assistance to Zimbabwe during the past twenty years.
A medical body in Zimbabwe has urged continued negotiations to find a deal acceptable to both sides so the nation's vital HIV treatment initiative can be sustained.
Broader Implications
This development comes after a similar situation in Kenya, where a high court suspended a similar health funding agreement after concerns were filed about the safety of Kenyans' medical information.
After returning to the presidency recently, US President Donald Trump has reduced foreign aid and closed the US Agency for International Development (USAID).
USAID had administered aid for the US government, but Trump argued its expenditure was "inefficient" and his administration was pursuing direct bilateral deals to boost transparency and accountability.
According to reports, 16 nations in Africa have so far signed these new agreements, representing more than $18.3bn in new funding.
Details of the Rejected Deal
The funds for Zimbabwe would have funded "tackling HIV/Aids, tuberculosis, malaria, healthcare for mothers and children, and preparing for epidemics".
"We believe this cooperation might have yielded immense benefits for the people of Zimbabwe, especially the 1.2 million men, women and children currently on HIV treatment via US-supported programmes," Tremont commented.
However, official spokesman Nick Mangwana argued the arrangement was "unequal".
"The proposal required Zimbabwe to surrender its genetic material and health information for a long time, with no corresponding guarantee of access to any medical innovations – such as vaccines, diagnostics, or treatments – that could be developed from that shared data," his statement read.
"Effectively, our nation would provide the raw materials for scientific discovery without any assurance that the resulting innovations would be accessible to our people if a new health crisis emerge."
Sovereignty and Global Health
He also noted that the American exit from the global health body and its push of bilateral deals were upending frameworks already set up through the international health agency.
Mangwana gave as an example its Pandemic Benefit-Sharing scheme created to manage potential global health emergencies.
"This mechanism is intended to guarantee that when a country provides its data, the benefits – such as vaccines and treatments – are shared equitably, not commercialised solely by those with the resources to develop them."
These objections over the US deal "must not be interpreted as hostility towards the US," Mangwana stressed.
"We encourage further discussions with our American counterparts on how future co-operation might be arranged in a way that honours the sovereignty and interests of each country."
Health Experts Response
Medical experts stated it acknowledged the government's concerns, but recommended that talks should continue since a large portion of the country's Aids initiatives were funded by foreign aid.
"Where specific concerns arise, such as those involving data governance or agreement terms, these can often be resolved via technical clarification and mutually agreed protections," the group commented.
The halted deal underscores the complex challenges between accepting crucial foreign assistance and protecting local interests in an ever more data-driven world.